Xenon Pharmaceuticals (XENE) FDA announcement summary

Introduction and purpose

• Azetukalner NDA submitted to the FDA for focal seizures; announcement also covered updates to epilepsy and psychiatry programs and potential first product launch in epilepsy.

Details of approval or decision

• NDA submission based on positive results from pivotal Phase IIb X-TOLE and Phase III X-TOLE2, global randomized, double-blind, placebo-controlled trials.

• New enrollment in MDD and bipolar-depression studies temporarily paused as a precaution after DSMB review of neuropsychiatric adverse events; FDA and study sites notified.

• Patients already enrolled in randomized and associated open-label psychiatry studies remain on study; enrollment continues in epilepsy trials X-TOLE3 and X-ACKT.

• X-NOVA2 enrollment to close at ~360 participants, retaining expected 90% power to detect a 2.5-point placebo-corrected HAM-D17 difference.

Impact on industry and stakeholders

• Potential add-on option for focal-seizure patients not controlled with initial treatment; differentiated mechanism, once-daily dosing and no dose adjustments for other antiseizure medications.

• Epilepsy launch plans unchanged; physician feedback cited efficacy, generally well-tolerated safety, once-daily dosing and ease of use.

• Management views the psychiatry pause as temporary and remains optimistic about the program; dosing changes aim to improve tolerability.